UAE Infectious Disease Drugs Market Analysis Report [2022 to 2030

UAE Infectious Disease Drugs Market Analysis

$ 3999

UAE Infectious Disease Drugs Market valued at $0.59 Bn in 2023, projected to reach $0.85 Bn by 2030 with a 5.27% CAGR. The market is being driven by the prevalence of infectious diseases, government initiatives, and rising healthcare expenditure. The market is dominated by key players like Hikma Pharmaceuticals, Julphar Gulf Pharmaceutical Industries, Neopharma, AbbVie Inc., Gilead Sciences, GlaxoSmithKline plc, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, and Janssen Pharmaceuticals.

ID: IN10AEPH012 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Aneri Parekh

Buy Now

UAE Infectious Disease Drugs Market Executive Summary

UAE Infectious Disease Drugs Market valued at $0.59 Bn in 2023, projected to reach $0.85 Bn by 2030 with a 5.27% CAGR.

The United Arab Emirates usually provides its population with infectious disease drugs through a mix of imported and locally produced pharmaceuticals. Respiratory, gastrointestinal, vector-borne, and vaccine-preventable illnesses are among the most common infectious diseases in the United Arab Emirates. Therefore, among the medicine classes used to treat and prevent these infections are vaccinations, antibiotics, antifungals, and antiviral agents.

Effective treatment solutions are in greater demand due to the expanding population and the increased emphasis on public health initiatives. In addition, the market is seeing large expenditures in R&D, which is resulting in the release of novel treatments. Pharmaceutical businesses looking to meet the changing healthcare demands of the UAE population can find attractive prospects in this market, despite obstacles including pricing pressure and regulatory barriers.

The global market for pharmaceuticals that cure infectious diseases was valued at $118.75 Bn in 2023. This expansion is the result of both, a rise in diagnoses and government initiatives aimed at educating the public about the management of infectious diseases. A shifting market environment is indicated by the growing degree of generic competition. Removing obstacles to affordability and enhancing treatment accessibility will be necessary for long-term growth, particularly in emerging nations. This will encourage further innovations and advancements in the sector.

Multinational pharmaceutical corporation Hikma Pharmaceuticals has a significant presence in the United Arab Emirates (UAE). The company is a significant participant in the pharmaceutical sector in the Middle East and North Africa (MENA) area. It develops, produces, and distributes a variety of branded and generic medications, including those for infectious diseases. In the United Arab Emirates, Hikma's range of infectious illness treatments includes azithromycin, amoxicillin, clavulanate potassium, fluconazole, and oseltamivir. The company will further solidify its position in the UAE market by developing and registering new medicines for infectious diseases.

UAE infectious disease drugs market

Market Dynamics

Market Growth Drivers:

Prevalence of Infectious Diseases: The need for medications to treat infectious diseases is fuelled by the frequency of these illnesses in the United Arab Emirates. Infectious diseases can spread due to climate, international travel, and population density.

Government Measures and Healthcare Infrastructure: The market for infectious disease medications is expanding as a result of the UAE government's measures to enhance healthcare services and infrastructure.

Growing Healthcare Expenditure: The pharmaceutical business, which includes the market for infectious disease medications, is growing as a result of rising healthcare spending in the United Arab Emirates. Improved access to healthcare services, such as the diagnosis and treatment of infectious diseases, is made possible by higher healthcare spending.

Market Restraints:

Regulatory Obstacles: Strict regulations and lengthy approval procedures for novel medications may impede the expansion of the industry.

Exorbitant Cost of Drug Development: Research and development expenses are high when creating new medications to treat infectious diseases. Pharmaceutical corporations may be discouraged from investing in medication development.

Trade Barriers and Intellectual Property Issues: Patent expirations, trade restrictions, and issues with intellectual property can affect market competition and accessibility to novel treatments for infectious diseases.

Notable Recent Updates

January 2023, the multinational pharmaceutical firm Hikma Pharmaceuticals PLC (Hikma) announced that it had entered into a new exclusive licensing arrangement for Vegzelma® (CT-P16, bevacizumab) with the global biopharmaceutical company Celltrion Healthcare Co., Ltd.

Healthcare Policies and Regulatory Landscape

The Ministry of Health and Prevention (MoHAP) of the United Arab Emirates (UAE) is in charge of overseeing pharmaceutical regulations. The process is submitting the request online through the MoHAP website, meeting all prerequisites, covering all associated expenses, and forwarding the report to the appropriate ministerial committee. To get a drug approved, compliance with Good Manufacturing Practices (GMP) is essential. Adherence to stringent quality standards is crucial for pharmaceutical manufacturing facilities to ensure product consistency and quality, thereby complicating the process.

Competitive Landscape

Key Players:

Hikma Pharmaceuticals
Julphar Gulf Pharmaceutical Industries
Neopharma
AbbVie Inc.
Gilead Sciences
GlaxoSmithKline plc
Merck & Co.
F. Hoffman-La Roche Ltd.
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Drug Market Segmentation

By Disease

HIV
Influenza
Hepatitis
Tuberculosis
Malaria
Other

By Treatment

Antibacterial
Antiviral
Antiparasitic
Other

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.